Merck accelerates cancer immunotherapy program with collaborations

Merck (MRK) says it has entered three separate collaboration agreements with Pfizer (PFE), Amgen (AMGN) and Incyte (INCY) to evaluate MRK's investigational MK-3475 immunotherapy cancer treatment, part of a new class of experimental drugs that unleash the body's immune system to target cancer cells.

MRK will collaborate on studies of MK-3475 in combination with therapies from the other drugmakers; financial terms weren't provided about the collaborations.

R&D chief Roger Perlmutter says MRK is looking at MK-3475 across a wide range of cancers, both as a standalone therapy and in combination with other treatments.

Earlier: MRK net profits falls 14%.

From other sites
Comments (1)
  • stockfan1
    , contributor
    Comments (91) | Send Message
    How about MRK exploring cancer immunotherapy vaccines such as from celldex. Merck is already in vaccine space with HPV vaccine. I believe Celldex, Galena will be accretive to Merck portfolio of products
    5 Feb 2014, 01:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs